Country-specific medical device registration costs rarely appear in pitch decks. Local representative retainers, certified translations, country fees, and ongoing annual renewals typically add EUR 30,000 to EUR 120,000 per market in year one and EUR 15,000 to EUR 60,000 per year thereafter — before a single unit ships.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • CE marking gets you access to the EU single market, but most non-EU markets and several EU member states layer on national registration requirements with their own costs.
  • Local representative retainers typically range from EUR 3,000 to EUR 18,000 per market per year, and many contracts include device volume surcharges.
  • Certified translations of IFU, labelling, and SSCP into every target language can add EUR 5,000 to EUR 25,000 per market for a single device family.
  • Government registration fees vary wildly: Switzerland is modest, UK MHRA fees are per-device-type, and some markets charge percentage-based duties on wholesale value.
  • Ongoing annual fees (representative retainers, renewal fees, PMS reporting to local authorities) compound across markets and rarely decrease over time.

Why this matters

Every founder I coach through international expansion hits the same moment. The CFO opens a spreadsheet, lists six target markets, and assumes the regulatory cost per market is "maybe EUR 10,000 for paperwork." Then reality arrives. The Swiss authorised representative sends a retainer quote. The German distributor refuses to ship without a DMIDS registration. The French ANSM asks for an IFU in French with specific vigilance contact details. The UK Responsible Person wants a 24-month contract minimum. Suddenly the spreadsheet has another zero.

This is the cost category that kills expansion budgets quietly. Not because it is hidden by anyone deliberately, but because founders rarely talk about it publicly and investors rarely ask about it specifically. The numbers live in contracts and annual invoices, not in regulatory strategy slides.

The Subtract to Ship discipline here is simple. Before you commit to a market, model the full lifetime cost, not the entry cost. Then decide whether that market earns its place in your roadmap.

What MDR actually says

MDR (EU) 2017/745 establishes the CE mark as a single-market authorisation. Article 5 ("Placing on the market and putting into service") means a CE-marked device that complies with the regulation can in principle be made available across all EU member states without re-certification. That is the promise.

Reality is more nuanced. Several MDR provisions create country-level obligations layered on top of CE marking:

  • Article 11 requires non-EU manufacturers to designate an EU Authorised Representative. That is an EU-wide obligation, but the contract, liability and retainer are all commercial.
  • Article 29 requires registration of the device and the manufacturer in Eudamed. However, until all Eudamed modules are fully operative and mandatory, several member states continue to operate national registration systems in parallel.
  • Article 31 requires registration of manufacturers, authorised representatives and importers. Again, national systems continue to function where Eudamed is not yet mandatory.
  • Language requirements are determined by each member state under Annex I Chapter III §23. Every country decides which official language(s) are required for labelling and IFU, and this is a national, not EU-wide, decision.

Outside the EU, none of this helps. Switzerland (CH-REP), UK (UKRP), and every market beyond Europe has its own regime, its own fees and its own representative requirements. The CE mark is often accepted as supporting evidence, but never as sole authorisation.

A worked example

Let me walk through a realistic scenario with a Class IIa software-based medical device from a 12-person Austrian startup. CE mark is secured. The board wants "Europe plus selected adjacent markets" in the first year post-certification. The target list: Germany, France, Italy, Switzerland, United Kingdom, and the Netherlands.

Germany. DMIDS registration with BfArM. Modest government fee. But German regulators expect IFU, labelling and website claims in German. Certified medical translation for the IFU: approximately EUR 4,000. Labelling update and artwork revision: EUR 2,500. No mandatory local representative, but most hospitals demand a German-speaking point of contact, which usually means retaining a distributor or local RA service. Year 1 all-in: approximately EUR 12,000 to EUR 18,000.

France. ANSM notification. French translation of IFU, SSCP (if applicable), and vigilance documentation: EUR 5,500. French vigilance reporting obligations require a documented French-speaking contact. Year 1: approximately EUR 14,000 to EUR 22,000.

Italy. Repertorio dei Dispositivi Medici notification. Italian translation. A government contribution fee applies, calculated as a small percentage of device turnover in Italy. Year 1: approximately EUR 10,000 to EUR 18,000, but the percentage-based fee means scaling into Italy has a permanent tax drag that most founders forget to model.

Switzerland. CH-REP is mandatory under Swiss MedDO. Retainers from established CH-REPs run EUR 4,000 to EUR 12,000 per year depending on device class and volume. Importer registration with Swissmedic. German, French, and Italian labelling. Year 1: approximately EUR 18,000 to EUR 30,000.

United Kingdom. UK Responsible Person required. Retainers typically EUR 3,500 to EUR 9,000 per year. MHRA device registration fees are charged per device class and per GMDN code group. Year 1: approximately EUR 10,000 to EUR 20,000.

Netherlands. Within CE scope, no national registration fee, but Dutch language IFU is strongly expected for patient-facing content. Year 1: approximately EUR 3,000 to EUR 6,000 for translation only.

Total year 1 across six markets: conservatively EUR 67,000, realistically closer to EUR 114,000. Year 2 onwards (ongoing representative retainers, renewals, translation updates for new software versions): EUR 35,000 to EUR 75,000 annually. Across a five-year horizon, this single budget line comes out at EUR 200,000 to EUR 430,000.

That is the number that belongs in the expansion slide. Not "registration: EUR 10,000."

The Subtract to Ship playbook

Step 1: Build a true unit economics model per market. Before committing, take every candidate market through a line-by-line cost sheet: local representative retainer, translation costs for every required language, government fees (one-off and annual), any percentage-based duties, vigilance reporting overhead, and your internal time. Compare that total against forecasted 3-year gross margin from the market. If the market cannot carry three years of its own regulatory cost, it does not belong on the roadmap yet.

Step 2: Sequence by margin, not by geography. The instinct is to enter neighbouring countries first. The discipline is to enter the markets where your unit margin comfortably absorbs the country cost and where the decision-making unit actually buys faster. Subtract the markets that look close on the map but pay slowly or regulate aggressively.

Step 3: Negotiate representative contracts with an exit clause. The default CH-REP, UKRP and EU AR contracts are 24 to 36 months with auto-renewal. That is not a law, that is a commercial default. Negotiate 12-month terms with a clean exit and a pre-agreed data handover. If a representative refuses, that tells you something about their interest in your success.

Step 4: Treat translations as a lifecycle cost, not a one-off. Every software release, every label change, every updated warning triggers re-translation across every market. Build a translation memory system from day one and standardise your labelling so that only genuinely new content needs certified translation. This alone can cut ongoing translation costs by 40 to 60 percent over five years.

Step 5: Centralise vigilance and PMS reporting. Article 11 MDR gives the Authorised Representative specific responsibilities around vigilance and incident communication. Structure your PMS and vigilance system once, then feed into each local representative via templates. Do not build a different vigilance workflow for each market.

Step 6: Revisit the roadmap annually. Markets that made sense last year may not make sense this year. Annual renewals are natural decision points. If a market is not carrying its weight, exit cleanly. Staying in a market out of pride costs real money.

Reality Check

  1. Have you modelled 5-year regulatory costs per target market, or only year 1 entry costs?
  2. Do you know the exact language requirements for every market on your roadmap, including for software UI, IFU, SSCP, and patient-facing materials?
  3. Have you received written retainer quotes from authorised representatives in every non-EU market you plan to enter?
  4. Can you name which markets charge percentage-based duties or ongoing fees tied to your device turnover?
  5. Do your representative contracts have exit clauses, or are you locked into auto-renewal?
  6. Is your translation workflow structured so that minor label updates do not trigger full re-translation across all markets?
  7. Have you built vigilance and PMS reporting as a single centralised process that feeds each market, or as parallel per-market workflows?
  8. If you had to exit a market tomorrow, do you know the contractual cost of doing so?

Frequently Asked Questions

Does CE marking cover all EU member states without any further registration? Legally, CE marking permits placing on the market across the EU. In practice, several member states maintain national notification systems (Germany, France, Italy and others) pending full Eudamed rollout, and each has its own language requirements for IFU and labelling.

How much does a Swiss CH-REP typically cost per year? Retainer fees from established CH-REPs run from approximately EUR 4,000 to EUR 12,000 per year for a single device family, with additional charges for higher-risk devices, higher volumes, or additional device variants. Always ask for a written fee schedule before signing.

Are local representative fees negotiable? Yes, but only before signing. Standard contracts are written to favour the representative with long auto-renewal periods. A startup with clear plans and a manageable device portfolio can negotiate 12-month initial terms, volume caps and clean exit clauses.

What translation costs should we expect for a Class IIa software device entering six European markets? For IFU, labelling, and patient-facing materials in six languages, budget EUR 15,000 to EUR 35,000 for the initial translation round, plus ongoing costs per software release or label update.

Do these costs scale with device class? Yes. Higher risk classes typically attract higher representative retainers, higher government fees and more extensive vigilance reporting obligations per market, because local authorities spend more time on each submission.

Is it cheaper to use one multi-market representative firm or separate specialists per market? Single-firm solutions offer lower coordination overhead and a single point of contact, but often come with higher aggregate retainers and weaker local knowledge. For most startups below 10 markets, a hybrid approach — specialist local representatives in the biggest markets and a multi-market firm for smaller ones — delivers the best cost-quality balance.

Sources

  1. Regulation (EU) 2017/745 on medical devices, consolidated text. Articles 5, 11, 29, 31, and Annex I Chapter III §23.
  2. Commission Implementing Regulation (EU) 2021/2078 — Eudamed rules.
  3. Swiss Federal Act on Therapeutic Products and the Medical Devices Ordinance (MedDO) — Swiss CH-REP obligations.
  4. UK Medical Devices Regulations 2002 (as amended) — MHRA registration and UKRP requirements.